Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EGFR C797S inhibitor
- Development stage
- Preclinical
- Lead developer
- Nutshell Therapeutics
- Modality
- Small Molecules
01
Overview
EGFR C797S inhibitor is a small-molecule targeted therapy being developed by Nutshell Therapeutics for the treatment of solid tumors. It is specifically designed to target the C797S mutation in the Epidermal Growth Factor Receptor (EGFR), which is a well-characterized resistance mechanism that emerges in patients with non-small cell lung cancer (NSCLC) following treatment with third-generation EGFR tyrosine kinase inhibitors (TKIs) such as osimertinib. By selectively inhibiting the C797S mutant form of the receptor, this drug candidate aims to overcome acquired resistance and provide a new therapeutic option for patients with advanced malignancies who have progressed on standard-of-care EGFR-targeted therapies. The program is currently in the Lead to Pre-Clinical Candidate (PCC) stage of development.
- Other names
- EGFR C797S inhibitor
02
Targets
EGFR C797S (Epidermal Growth Factor Receptor C797S)EGFR T790M/C797S (Epidermal growth factor receptor (EGFR) T790M/C797S mutant)Epidermal growth factor receptor (EGFR) L858R/C797S
Beyond the preview
Go deeper on EGFR C797S inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EGFR C797S inhibitor.